Press Releases

06/03/2024

Providers

Tempus Announces New Features to its Smart Physician Platform, Hub

Tempus, a leader in artificial intelligence and precision medicine, today announces a suite of new features in its physician platform, Hub. Trusted by thousands of oncologists and care teams, Hub is an AI-enabled platform that provides access to patient insights in a secure environment. Tempus is now unveiling a collection of new and enhanced f...

06/02/2024

Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care

Tempus, a leader in artificial intelligence and precision medicine, announced new testing solutions to help physicians identify patients with HER2 or FOLR1 expressing tumors, which may make such patients eligible for targeted therapies such as antibody–drug conjugates (ADCs). HER2 and FOLR1 testing by immunohistochemistry (IHC) is now available for all so...

06/01/2024

Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLC

Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm physicians with technology that supports the delivery of guideline-directed biomarker testing for patients with non-small cell lung cancer (NSCLC). The magnitude and frequency of updates to oncology guidelines ea...

05/31/2024

Tempus Announces the Clinical Launch of its MRD Testing Portfolio

xM MRD and NeXT Personal Dx tests are now available for physicians in the U.S. for early cancer recurrence detection and residual disease monitoring Tempus, a leader in artificial intelligence and precision medicine, today announced the clinical launch of its minimal residual disease (MRD) test portfolio, including Tempus’ xM t...

05/30/2024

Tempus Exhibits 16 Abstracts at the 2024 American Society of Clinical Oncology Annual Meeting

Tempus, a leader in artificial intelligence and precision medicine, today announced the company is scheduled to exhibit 16 abstracts at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting, which convenes from May 31-June 4 in Chicago, Illinois. This year, Tempus is presenting its latest research, including new data from its minimal residual disea...

04/16/2024

Tempus Introduces its AI-enabled Care Pathway Intelligence Platform, Tempus Next

Tempus, a leader in artificial intelligence and precision medicine, is introducing Tempus Next, a care pathway intelligence platform. By harnessing the power of AI, Tempus Next identifies care gaps and equips clinicians with actionable insights at the point of care, supporting access to the most up-to-date, guideline-directed treatments. T...

04/08/2024

Tempus Releases New Data at AACR Showcasing Ways to Analyze Multimodal Data to Highlight Potential Therapeutic Routes for HER2- Directed Antibody-Drug Conjugates in Several Tumor Types

Tempus, a leader in artificial intelligence and precision medicine, will present new data along with Pfizer at the AACR 2024 Annual Meeting. The abstract, titled “Analysis of HER2 prevalence by RNA expression across solid tumors,” found that by correlating HER2 protein levels by IHC/ISH and ERBB2 mRNA levels by NGS in tumo...

04/06/2024

Tempus Introduces Workspaces into its Lens Data Analytics Platform

Lens is trusted by nearly 100 institutions to uncover novel insights Tempus, a leader in artificial intelligence and precision medicine, is broadly introducing its new Workspaces feature in the Lens platform. Workspaces is a private, coding-based cloud environment designed to unblock research and accelerate innovation. This new interface provides r...

04/05/2024

Tempus Announces 18 Abstracts Accepted For Presentation at the American Association for Cancer Research Annual Meeting 2024

Tempus, a leader in artificial intelligence and precision medicine, today announced 18 abstracts were accepted for presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which convenes from April 5-10, in San Diego, California. Tempus researchers will demonstrate how the company’s AI-enabled precision medicine platform collects and a...

03/25/2024

Tempus Announces the Clinical Launch of p-MSI, its MSI-High Predictive Algorithm for Patients with Prostate Cancer

Tempus, a leader in artificial intelligence and precision medicine, today announces the clinical launch of p-MSI, a digital pathology algorithm using H&E whole slide images that is available with the company’s xT assay for patients with prostate cancer. This offering aims to identify patients who may be mor...

NEWS

Media Coverage

Additional Partnerships